- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02461693
Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT
13. Juni 2017 aktualisiert von: David Allison, Phd, University of Alabama at Birmingham
Evaluating the Role of Expectations in Response to Caffeine Consumption: A Randomized Control Trial
The purpose of this project is to examine the effect of expectancy on mood and alertness after consumption of caffeine "treatment" or placebo "control" pill, given that participants know their probability for receiving the caffeine versus placebo pill.
Participants will be randomly assigned a probability (ranging from 0-100%) of receiving caffeine vs. placebo, and this probability will be revealed to them before consumption of the assigned pill and subsequent cognitive testing.
At the time of consumption, neither study staff administering the intervention nor participants will know for certain which pill is given to each participant.
Pill assignment will depend on pre-determined randomization probabilities, which will be provided and assigned by the study statistician.
By revealing participants' individual probability of receiving the caffeine pill, we will induce positive or negative expectancies regarding likelihood for receipt of the caffeine pill.
These experimental manipulations will: 1) estimate the effect of expectancy on cognitive and affective outcomes, and 2) allow for a more direct estimate of the effect of the caffeine pill under real-world conditions than would a conventional randomized trial.
Studienübersicht
Status
Abgeschlossen
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Tatsächlich)
205
Phase
- Unzutreffend
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
18 Jahre und älter (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- 18 years-old or older
- available to participate on the dates specified
- willing to take a caffeine or placebo pills at study session
- willingness to abstain from caffeine for 12 hours prior to study visit (8:30pm-8:30am)
- UAB employees or students with some college education (including current enrollment)
Exclusion Criteria:
- self-reported use of ADHD medication
- self-reported use of anxiety medication
- self-reported use of sleep medication
- self-reported use of nicotine products
- self-reported lactose intolerance
- self-reported uncorrected vision
- self-reported pregnancy or trying to become pregnant
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Caffeine
One-time treatment with 200mg caffeine pill
|
200mg delivered as pill; one-time dose
|
|
Placebo-Komparator: Placebo
One-time treatment with lactose-based placebo pill
|
Lactose-based pill; one-time dose
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mood State Score on POMS-2 Test
Zeitfenster: 30 minutes post pill consumption
|
Profile of Mood States (POMS-2)- "Volunteers rated a series of 65 mood-related adjectives with regard to how they were feeling "right now" on a scale of 0 (not at all) to 4 (extremely).
The adjectives factor into six mood sub-scales: Tension-Anxiety; Depression-Dejection; Anger-Hostility; Vigor-Activity; Fatigue-Inertia; Confusion-Bewilderment and a Total Mood Disturbance score which aggregates the six sub-scales into a single variable."
- from our publication.
The minimum and maximum possible raw scores were: 0 and 40 for Tension-Anxiety, 0 and 52 for Depression-Dejection, 0 and 44 for Anger-Hostility, 0 and 36 for Vigor-Aactivity, 0 and 24 for Fatigue-Inertia, 0 and 40 for Confusion-Bewilderment, -36 and 200 for Total Mood Disturbance, and 0 and 24 for Friendliness.
For Friendliness and Vigor-Activity, the more positively a person feels, the higher the score.
For all other sub-scales and Total Mood Disturbance, the more negatively a person feels, the higher the score.
|
30 minutes post pill consumption
|
|
Vigilance Score on Computer-based Test Using Random, Visual Stimulus: Proportion Correct (Out of 60)
Zeitfenster: 45 to 105 minutes post pill consumption
|
Scanning Visual Vigilance Test.
"This test assesses vigilance, ability to sustain attention during long, boring, continuous tasks that generate minimal cognitive load (Fine et al, 1994; Lieberman et al, 1998; 2002).
The volunteer continuously scans a computer screen to detect an infrequent, difficult-to-detect stimulus that appears at random intervals and locations for 2 s.
On average, a stimulus was presented once per minute.
Upon detection of the stimulus, the volunteer pressed the space bar as rapidly as possible.
Whether a stimulus was detected and time required for detection was recorded.
Responses before or after stimulus occurrence were false alarms.
The test lasted 60 minutes."
- from our publication
|
45 to 105 minutes post pill consumption
|
|
Vigilance Score on Computer-based Test Using Random, Visual Stimulus: Number Correct, Number of False Alarm Hits
Zeitfenster: 45 to 105 minutes post pill consumption
|
Scanning Visual Vigilance Test.
"This test assesses vigilance, ability to sustain attention during long, boring, continuous tasks that generate minimal cognitive load (Fine et al, 1994; Lieberman et al, 1998; 2002).
The volunteer continuously scans a computer screen to detect an infrequent, difficult-to-detect stimulus that appears at random intervals and locations for 2 s.
On average, a stimulus was presented once per minute.
Upon detection of the stimulus, the volunteer pressed the space bar as rapidly as possible.
Whether a stimulus was detected and time required for detection was recorded.
Responses before or after stimulus occurrence were false alarms.
The test lasted 60 minutes."
- from our publication
|
45 to 105 minutes post pill consumption
|
|
Vigilance Score on Computer-based Test Using Random, Visual Stimulus: Mean Time to a Correct Hit
Zeitfenster: 45 to 105 minutes post pill consumption
|
Scanning Visual Vigilance Test.
"This test assesses vigilance, ability to sustain attention during long, boring, continuous tasks that generate minimal cognitive load (Fine et al, 1994; Lieberman et al, 1998; 2002).
The volunteer continuously scans a computer screen to detect an infrequent, difficult-to-detect stimulus that appears at random intervals and locations for 2 s.
On average, a stimulus was presented once per minute.
Upon detection of the stimulus, the volunteer pressed the space bar as rapidly as possible.
Whether a stimulus was detected and time required for detection was recorded.
Responses before or after stimulus occurrence were false alarms.
The test lasted 60 minutes."
- from our publication
|
45 to 105 minutes post pill consumption
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Ermittler
- Hauptermittler: David B Allison, PhD, University of Alabama at Birmingham
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Juni 2015
Primärer Abschluss (Tatsächlich)
1. Oktober 2015
Studienabschluss (Tatsächlich)
1. Oktober 2015
Studienanmeldedaten
Zuerst eingereicht
1. Juni 2015
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
2. Juni 2015
Zuerst gepostet (Schätzen)
3. Juni 2015
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
12. Juli 2017
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
13. Juni 2017
Zuletzt verifiziert
1. Juni 2017
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- F150410009
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Ja
Beschreibung des IPD-Plans
Raw de-identified data will be posted as a replication data set on ICPSR after publication of results in a journal.
Data will be free to download and accessible to anyone with access to ICPSR replication data sets.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .